Combined effects of HMG-CoA-reductase inhibition and renin–angiotensin system blockade on experimental atherosclerosis

This publication has 58 references indexed in Scilit:

• Fluvastatin Enhances the Inhibitory Effects of a Selective AT ₁ Receptor Blocker, Valsartan, on Atherosclerosis
  Hypertension, 2004
• Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating Activity
  Hypertension, 2004
• Safety of Telmisartan in Patients with Arterial Hypertension
  Drug Safety, 2004
• Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits
  Clinical Science, 2003
• Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris
  The American Journal of Cardiology, 2003
• Inflammatory imbalance between IL‐10 and TNFα in unstable angina potential plaque stabilizing effects of IL‐10
  European Journal of Clinical Investigation, 2002
• The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
  Nature, 2002
• Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice
  Stroke, 2000
• Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin???angiotensin-system gene expression and cardiovascular functions
  Journal Of Hypertension, 1995
• Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
  Science, 1992